December 18, 2024
Psilocin’s next target: Tryptamine Therapeutics (ASX:TYP) takes aim at IBS
Tryptamine Therapeutics (ASX:TYP) delivers promising interim results from its Phase 2a trial, with 75% of IBS patients reporting reduced abdominal pain and anxiety, marking a significant step for TRP-8803’s clinical pathway.